BioSpace News Archive

AgNovos Healthcare, a developer of medical technology products leveraging regenerative medicine to treat the local effects of bone disease, announced today that its newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) kit has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration.

Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV ® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that it has launched the syndication of new senior secured credit facilities, comprised of a senior secured revolving facility and a senior secured term loan B facility.

Halberd Corporation is pleased to announce Youngstown State University’s Dr. William G. Sturrus will lead the Radio Frequency research on Halberd’s Disease Elimination multi-organization Task Force.

Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug application (IND) for PVSRIPO in patients with solid tumors.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).

In partnership with Ziehm Imaging, Carestream Health is pleased to announce the addition of a mobile C-arm into its growing innovative product portfolio.

-Data presentation to be released online at 10:00 AM ET on Friday, April 23, 2021 -Live Q&A session with presenter to be held on Saturday, April 24, 2021 at 3:00 PM ET

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Boston Business Journal (BBJ) has named Kymera Therapeutics to its 2021 Best Places to Work, an exclusive ranking of the Massachusetts companies that have built outstanding work environments for their people.

BioShin Limited, biopharmaceutical company focused on the discovery, development and commercialization of novel, life-improving treatments for patients with neuro-immune diseases in China and the Asia-Pacific region, today announced the appointment of David Chung as Chief Strategy Officer and Head of Business Development.